Day One shareholders approve officer exculpation charter amendment; elect two directors

Day One Biopharmaceuticals, Inc.

Stockholders approved Certificate of Amendment to limit officer liability under Delaware DGCL, filed June 22, 2023.
Scott Garland and John Josey elected as Class II directors for three-year terms expiring 2026.
Garland received 63,229,607 votes for; Josey received 52,093,255 votes for.
Ratification of Ernst & Young as independent auditor for FY2023: 66,370,613 votes for, 12,503 against.
Amendment and director elections effective at the 2023 Annual Meeting held June 22, 2023.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Day One Biopharmaceuticals, Inc.: Amended certificate of incorporation to permit exculpation of officers as allowed under Delaware law (effective 2023-06-22).

Change: charter amendment
Effective: 2023-06-22

Exact text from the filing

On June 22, 2023, the Company filed the Certificate of Amendment with the Delaware Secretary of State to effect such amendment.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Day One Biopharmaceuticals, Inc. shareholders approved Approval of an amendment to the Company’s Restated Certificate of Incorporation to limit the liability of certain officers of the Company as permitted pursuant to recent amendments to the Delaware General Corporation Law at the 2023-06-22 meeting.

Proposal: charter amendment
Outcome: passed
Meeting: 2023-06-22

Exact text from the filing

Approval of an amendment to the Company’s Restated Certificate of Incorporation to limit the liability of certain officers of the Company as permitted pursuant to recent amendments to the Delaware General Corporation Law. The vote tally was as follows: Shares For Shares Against Shares Abstaining Broker Non-Votes 56,885,240 6,732,313 6,800 2,758,766

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Day One Biopharmaceuticals, Inc. shareholders approved Election of two Class II Directors, Scott Garland and John Josey, Ph.D., M.B.A., each to serve a three-year term at the 2023-06-22 meeting.

Proposal: director election
Outcome: passed
Meeting: 2023-06-22

Exact text from the filing

Election of two Class II Directors, Scott Garland and John Josey, Ph.D., M.B.A., each to serve a three-year term, which will expire at the 2026 Annual Meeting of Stockholders and until such time as their respective successors have been duly elected and qualified or until such director’s earlier resignation or removal. The vote tally was as follows: Nominees Shares For Shares Withheld Broker Non-Votes Scott Garland 63,229,607 394,746 2,758,766 John Josey, Ph.D., M.B.A. 52,093,255 11,531,098 2,758,766

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Day One Biopharmaceuticals, Inc. shareholders approved Ratification of appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2023 at the 2023-06-22 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2023-06-22

Exact text from the filing

Ratification of appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2023. The vote tally was as follows: Shares For Shares Against Shares Abstaining 66,370,613 12,503 3

View on SEC.gov

Browse all governance changes →

Source: SEC EDGAR

accession 0001193125-23-173808

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.